Important note: Information in this article was accurate in March 2001. The state of the art may have changed since the publication date.AIDSWEEKLY Plus; Monday, March 19, 2001
This article was prepared by AIDS Weekly editors from staff and other reports.
R.E. Polk and colleagues at Virginia Commonwealth University studied the interactions between amprenavir and common prophylactic MAC treatments.
They found that amprenavir can prevent the clearance of rifabutin, forcing almost half of the patients studied to discontinue therapy. Conversely, rifampin was found to hasten amprenavir clearance.
Concomitant administration of amprenavir and rifabutin increased rifabutin's steady state area under the curve by almost threefold, study data showed.
Rifampin, meanwhile, was shown to decrease amprenavir's area under the curve by more than 80% ("Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males," Antimicrob Agents Chemother 2001 Feb;45(2):502-508.
Polk et al. also found that while amprenavir reduces the results of the erythromycin breath test by over 80%, both rifabutin and rifampin increase the results of this test by more than 150%.
"Amprenavir plus rifabutin was poorly tolerated, and five of 11 subjects discontinued therapy," Polk and colleagues concluded. "Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated."
The corresponding author for this report is R.E. Polk, Virginia Commonwealth University, Medical College of Virginia, School of Pharmacy, P.O. Box 980533, Campus, Richmond, VA 23298, USA.
A search at NewsRx.net using the search terms "AIDS and HIV Therapies" yielded over 1,100 articles in six specialized reports.
Key points reported in this study include:
This article was prepared by AIDS Weekly editors from staff and other reports.
0100319
AW010308
Copyright © 2001 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1990,2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.